Patents by Inventor Jean-Marc Herbert

Jean-Marc Herbert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060199962
    Abstract: The invention is directed to a compound of formula I, wherein R, R1, R2, R3 and R4 are as defined herein, or a pharmaceutically acceptable salt thereof, and its pharmaceutically composition, preparation and uses as an inhibitor of FGFs (fibroblast growth factors).
    Type: Application
    Filed: March 17, 2006
    Publication date: September 7, 2006
    Applicant: Sanofi-aventis
    Inventors: Chantal Alcouffe, Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert
  • Publication number: 20060167007
    Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4) alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents the aromatic group 1,3-thiazol-2-yl of formula: Preparation process and therapeutic application.
    Type: Application
    Filed: June 5, 2003
    Publication date: July 27, 2006
    Applicant: sanofi-aventis
    Inventors: Francoise Bono, Michael Bosch, Victor Dos Santos, Jean-Marc Herbert, Dino Nisato, Bernard Tonnerre, Jean Wagnon
  • Publication number: 20060160768
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.
    Type: Application
    Filed: January 14, 2005
    Publication date: July 20, 2006
    Inventors: Philippe Duchaussoy, Jean-Marc Herbert, Maurice Petitou, Pierre Savi
  • Publication number: 20050203126
    Abstract: Compounds of formula I or salts thereof: in which R1 represents —OH, (C1-C5)alkoxy, carboxyl, (C2-C6)alkoxycarbonyl, —NR5R6, —NH—SO2-Alk, —NH—SO2-Ph, —NH—CO-Ph, —N(Alk)-CO-Ph, —NH—CO—NH-Ph, —NH—CO-Alk, —NH—CO2-Alk, —O—(CH2)n-cAlk, —O-Alk-COOR7, —O-Alk-O—R8, —O-Alk-OH, —O-Alk-C(NH2):NOH, —O-Alk-NR5R6, —O-Alk-CN, —O—(CH2)n-Ph, —O-Alk-CO—NR5R6, —CO—NH—(CH2)m—COOR7, —CO—NH-Alk R2 represents H, (C1-C5)alkyl, (C1-C5)alkyl halide, (C3-C6)cycloalkyl or phenyl which is optionally substituted, A represents —CO—, —SO— or —SO2—, R3 and R4 which are identical or different, each represent H, (C1-C5)alkoxy, amino, carboxyl, (C2-C6)alkoxycarbonyl, —OH, nitro, hydroxyamino, -Alk-COOR7, —NR5R6, —NH-Alk-COOR7, —NH—COO-Alk, —N(R11)—SO2-Alk-NR9R10, —N(R11)—SO2-Alk, —N(R11)-Alk-NR5R6, —N(R11)—CO-Alk-NR9R10, —N(R11)—CO-Alk, —N(R11)—CO—CF3, —NH-Alk-HetN, —O-Alk-NR9R10, —O-Alk-CO—NR5R6, —O-Alk-HetN, or R3 and R4 form together a 5- to 6-membered unsaturated heterocycle, are inhibitors of basic fibroblast growth factors.
    Type: Application
    Filed: April 2, 2003
    Publication date: September 15, 2005
    Inventors: Alain Badorc, Francoise Bono, Marie-Francoise Bordes, Nathalie Guillo, Jean-Marc Herbert
  • Publication number: 20050176722
    Abstract: The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.
    Type: Application
    Filed: June 5, 2003
    Publication date: August 11, 2005
    Applicant: sanofi-aventis
    Inventors: Francoise Bono, Michael Bosch, Victor Dos Santos, Jean-Marc Herbert, Dino Nisato, Bernard Tonnerre, Jean Wagnon
  • Patent number: 6844329
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: January 18, 2005
    Assignee: Sanofi-Synthelabo
    Inventors: Philippe Duchaussoy, Jean-Marc Herbert, Maurice Petitou, Pierre Savi
  • Publication number: 20040157868
    Abstract: The invention relates to the use of a compound of formula (I): 1
    Type: Application
    Filed: February 5, 2004
    Publication date: August 12, 2004
    Inventors: Francoise Bono-Combie, Jacqueline Fournier, Jean Marc Herbert, Isabelle Lamarche, Umberto Guzzi
  • Publication number: 20040092477
    Abstract: The invention relates to the use of direct or indirect selective inhibitors of factor Xa acting via antithrombin III, alone or in combination with one or more compounds with anti-platelet aggregation activity, for the preparation of medicines intended to prevent and to treat thromboembolic arterial diseases.
    Type: Application
    Filed: January 7, 2003
    Publication date: May 13, 2004
    Inventors: Andre Bernat, Jean Marc Herbert, Maurice Petitou, Ronald Van Amsterdam
  • Publication number: 20040068108
    Abstract: Synthetic polysaccharides are disclosed containing 8-24 monosaccharide units made up of a concatenation of disaccharides consisting of a uronic acid and a hexose, wherein the hydroxyl groups of the polysaccharides are etherified with a C1-6 alkyl group or esterified in the form of a sulpho group, each disaccharide being at least monoetherified; and salts thereof, are disclosed.
    Type: Application
    Filed: October 2, 2003
    Publication date: April 8, 2004
    Inventors: Philippe Duchaussoy, Jean Marc Herbert, Guy Jaurand, Maurice Petitou, Constant Van Boeckel
  • Patent number: 6693118
    Abstract: The invention relates to the use of a compound of formula (I): for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.
    Type: Grant
    Filed: November 20, 2001
    Date of Patent: February 17, 2004
    Assignee: Sanofi-Synthelabo
    Inventors: Françoise Bono-Combie, Jacqueline Fournier, Jean Marc Herbert, Isabelle Lamarche, Umberto Guzzi
  • Publication number: 20040024197
    Abstract: The present invention relates to novel synthetic polysaccharides with antithrombotic activity exhibiting at least one covalent bond with biotin or a biotin derivative and to a process employing avidin or streptavidin which makes it possible to neutralize these polysaccharides.
    Type: Application
    Filed: March 21, 2003
    Publication date: February 5, 2004
    Inventors: Phillppe Duchaussoy, Jean-Marc Herbert, Maurice Petitou, Pierre Savi
  • Patent number: 6541488
    Abstract: The invention relates to the use of direct or indirect selective inhibitors of factor Xa acting via antithrombin III, alone or in combination with one or more compounds with anti-platelet aggregation activity, for the preparation of medicines intended to prevent and to treat thromboembolic arterial diseases. The subject of the invention is also pharmaceutical compositions containing one or more direct or indirect selective inhibitors of factor Xa which act via antithrombin III in combination with one or more compounds with anti-platelet aggregation activity, and optionally one or more pharmaceutically acceptable vehicles.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: April 1, 2003
    Assignees: Sanofi-Synthelabo, Akzo Nobel
    Inventors: André Bernat, Jean Marc Herbert, Maurice Petitou, Ronald Van Amsterdam
  • Patent number: 6534481
    Abstract: A synthetic polysaccharide including an antithrombin III binding domain consisting of a concatenation of five monosaccharides supporting a total of two carboxylic acid functions and at least four sulpho groups, said domain being directly bound at the non-reducing end by a thrombin binding domain including a concatenation of 10-25 monosaccharide units selected from hexoses, pentoses or deoxy sugars of which all the hydroxyl groups are etherified by a C1-6 alkyl group or esterified in the form of sulpho groups, as well as salts and particularly pharmaceutically acceptable salts thereof, are disclosed.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: March 18, 2003
    Assignees: Sanofi-Synthelabo, Akzo Nobel
    Inventors: Pierre Alexandre Driguez, Philippe Duchaussoy, Jean Marc Herbert, Maurice Petitou, Constant Van Boeckel, Peter Grootenhuis, Johannes Basten, Cornelia Dreef-Tromp
  • Patent number: 6528497
    Abstract: Novel synthetic polysaccharides for use in the treatment of pathologies associated with a coagulation dysfunction.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: March 4, 2003
    Assignees: Sanofi-Synthelabo, Akzo Nobel N.V.
    Inventors: Johannes Basten, Cornelia Dreef-Tromp, Pierre Alexandre Driguez, Philippe Duchaussoy, Jean Marc Herbert, Maurice Petitou, Constant Van Boeckel
  • Patent number: 6482986
    Abstract: The invention concerns compounds of formula (I) wherein A, X, Y, n, R1, R2 and R3 are as defined in claim 1. Said compounds are specifically binding to sigma receptors particularly those of the peripheral nervous system.
    Type: Grant
    Filed: February 27, 2002
    Date of Patent: November 19, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Robert Boigegrain, Bernard Bourrie, Martine Bourrie, Pierre Casellas, Jean Marc Herbert, Pierre Lair, Dino Nisato, Raymond Paul, Jean Claude Vernieres
  • Publication number: 20020091143
    Abstract: The invention relates to the use of a compound of formula (I): 1
    Type: Application
    Filed: November 20, 2001
    Publication date: July 11, 2002
    Inventors: Francoise Bono-Combie, Jacqueline Fournier, Jean Marc Herbert, Isabelle Lamarche, Umberto Guzzi
  • Patent number: 6391339
    Abstract: The invention relates to the use of a certain oligosaccharide for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment.
    Type: Grant
    Filed: November 24, 1999
    Date of Patent: May 21, 2002
    Assignee: Akzo Nobel N.V.
    Inventors: Jacobus Christianus Johannes Stiekema, Jean Marc Herbert
  • Publication number: 20020040012
    Abstract: A method for preventing clotting in an extracorporeal blood circuit by administering a synthetic oligosaccharide that is a selective inhibitor of factor Xa, acting via antithrombin III.
    Type: Application
    Filed: November 2, 2001
    Publication date: April 4, 2002
    Inventors: Jacobus Christianus Johannes Stiekema, Jean Marc Herbert
  • Patent number: 6342505
    Abstract: The invention relates to the use of a compound of formula (I): for the preparation of pharmaceutical compositions for increasing the circulating, cellular and extracellular levels of TGF-&bgr;1.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: January 29, 2002
    Assignee: Sanofi-Synthelabo
    Inventors: Françoise Bono-Combie, Jacqueline Fournier, Jean Marc Herbert, Isabelle Lamarche, Umberto Guzzi
  • Patent number: 6235793
    Abstract: The invention relates to the use of &bgr;3-adrenergic receptor agonists for the preparation of healing drugs and to the pharmaceutical compositions for said use.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: May 22, 2001
    Assignee: Sanofi-Synthelabo
    Inventors: André Bernat, Jean-Marc Herbert, Michèle Arnone